[The value of F-18 fluorodeoxyglucose in positron emission tomography diagnosis of breast carcinoma].

Wien Med Wochenschr

Abteilung für Nuklearmedizin und Endokrinologie, PET Zentrum Linz, Krankenhaus der Barmherzigen Schwestern, Seilerstätte 4, A-4010 Linz.

Published: October 2002

Fluorodeoxyglucose-positron emission tomography (F-18-FDG-PET) has become an important issue in the diagnosis of malignant tumors within the last years. In breast cancer PET has been established in the diagnosis of the primary tumor as well as in recurrences with a sensitivity of 90% and a specificity of 75%-100%; additional a sensitivity of more than 90% and a specificity of about 75% is also seen in axillary lymph nodes detection. With our own results we were able to prove sensitivity of positron emission tomography in diagnosing the primary lesion, locoregional lymph nodes and the staging of metastases. Furthermore, positron emission tomography seems to be superior to conventional imaging modalities in staging primary and recurrent breast cancer, distant metastases and lymph nodes outside the axilla.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1563-258x.2002.02016.xDOI Listing

Publication Analysis

Top Keywords

emission tomography
16
positron emission
12
lymph nodes
12
breast cancer
8
sensitivity 90%
8
90% specificity
8
[the f-18
4
f-18 fluorodeoxyglucose
4
fluorodeoxyglucose positron
4
emission
4

Similar Publications

Objective: This study aimed to develop a simple machine-learning model incorporating lymph node metastasis status with F-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and clinical information for predicting regional lymph node metastasis in patients with colon cancer.

Methods: This retrospective study included 193 patients diagnosed with colon cancer between January 2014 and December 2017. All patients underwent F-18 FDG PET/CT and blood test before surgery.

View Article and Find Full Text PDF

Cognitive variation reflects amyloid, tau, and neurodegenerative biomarkers in Alzheimer's disease.

Geroscience

January 2025

Psychology, School of Social Sciences, Nanyang Technological University, 48 Nanyang Avenue S639818, Singapore, Singapore.

In Alzheimer's disease (AD), the accumulation of neuropathological markers such as amyloid-β plaques, neurofibrillary tangles, and cortical neurodegeneration occurs over many years before overt manifestation of cognitive impairment. There is thus a need for neuropsychological markers that are indicative of pathological changes in the early stages of the disease. Intra-individual cognitive variability (IICV), defined as the variation of an individual's performance across cognitive domains, is a promising neuropsychological marker measuring heterogeneous changes in cognition that may reflect these early pathological changes.

View Article and Find Full Text PDF

Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.

Ann Nucl Med

January 2025

Department of Radiological Sciences, School of Health Science, Fukushima Medical University, 10-6 Sakae, Fukushima City, Fukushima, 960-8516, Japan.

Objective: This study aims to accurately classify ATN profiles using highly specific amyloid and tau PET ligands and MRI in patients with cognitive impairment and suspected Alzheimer's disease (AD). It also aims to explore the relationship between quantified amyloid and tau deposition and cognitive function.

Methods: Twenty-seven patients (15 women and 12 men; age range: 64-81 years) were included in this study.

View Article and Find Full Text PDF

Purpose: We hypothesised that applying radiomics to [F]PSMA-1007 PET/CT images could help distinguish Unspecific Bone Uptakes (UBUs) from bone metastases in prostate cancer (PCa) patients. We compared the performance of radiomic features to human visual interpretation.

Materials And Methods: We retrospectively analysed 102 hormone-sensitive PCa patients who underwent [F]PSMA-1007 PET/CT and exhibited at least one focal bone uptake with known clinical follow-up (reference standard).

View Article and Find Full Text PDF

Introduction: Equivocal or negative pituitary magnetic resonance imaging (MRI) findings raise a significant challenge in the management of persistent or recurrent Cushing's disease (CD), compromising the chances of success of a further transsphenoidal surgery (TSS). The aim of our study was to determine the diagnostic utility of 11C-methionine (MET) positron emission tomography coupled with computerized tomography (PET/CT) in localizing the residual or relapsing corticotroph adenoma.

Methods: We retrospectively analyzed the results of 11C-MET PET/CT performed in two tertiary medical centers between May 2002 and November 2023 in 22 patients with a persisting or recurrent CD after initial TSS and equivocal or negative pituitary MRI findings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!